MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
SJ Rodig, D Gusenleitner, DG Jackson… - Science translational …, 2018 - science.org
Combination anti–cytotoxic T lymphocyte antigen 4 (CTLA-4) and anti–programmed cell
death protein 1 (PD-1) therapy promotes antitumor immunity and provides superior benefit to …
death protein 1 (PD-1) therapy promotes antitumor immunity and provides superior benefit to …
The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update
High-throughput data production technologies, particularly 'next-generation'DNA
sequencing, have ushered in widespread and disruptive changes to biomedical research …
sequencing, have ushered in widespread and disruptive changes to biomedical research …
Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus–unrelated head and neck cancer: a multicenter, phase II trial
R Uppaluri, KM Campbell, AM Egloff, P Zolkind… - Clinical Cancer …, 2020 - AACR
Purpose: Pembrolizumab improved survival in patients with recurrent or metastatic head and
neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if …
neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if …
pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens
Cancer immunotherapy has gained significant momentum from recent clinical successes of
checkpoint blockade inhibition. Massively parallel sequence analysis suggests a connection …
checkpoint blockade inhibition. Massively parallel sequence analysis suggests a connection …
NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …
GenVisR: genomic visualizations in R
Visualizing and summarizing data from genomic studies continues to be a challenge. Here,
we introduce the GenVisR package to addresses this challenge by providing highly …
we introduce the GenVisR package to addresses this challenge by providing highly …
GenPipes: an open-source framework for distributed and scalable genomic analyses
Background With the decreasing cost of sequencing and the rapid developments in
genomics technologies and protocols, the need for validated bioinformatics software that …
genomics technologies and protocols, the need for validated bioinformatics software that …
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
ABCB1 encodes Multidrug Resistance protein (MDR1), an ATP-binding cassette member
involved in the cellular efflux of chemotherapeutic drugs. Here we report that ovarian and …
involved in the cellular efflux of chemotherapeutic drugs. Here we report that ovarian and …
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphoma, yet it
remains only partially characterized at the genomic level. To improve our understanding of …
remains only partially characterized at the genomic level. To improve our understanding of …
Optimizing cancer genome sequencing and analysis
Tumors are typically sequenced to depths of 75x–100x (exome) or 30x–50x (whole
genome). We demonstrate that current sequencing paradigms are inadequate for tumors …
genome). We demonstrate that current sequencing paradigms are inadequate for tumors …